News & Updates
Filter by Specialty:
Metformin discontinuation ups cardio-renal events in CKD patients with diabetes
Putting an end to the use of metformin may lead to a higher risk of cardio-renal events in patients with diabetes and advanced chronic kidney disease (CKD), regardless of their cardiovascular disease (CVD) status, suggests a study presented at ADA 2023.
Metformin discontinuation ups cardio-renal events in CKD patients with diabetes
18 Jul 2023
Advanced liver fibrosis a red flag for poor outcomes in T2D
Among individuals with type 2 diabetes (T2D), the risk of poor outcomes such as heart failure and hospitalizations is high in the presence of advanced liver fibrosis, according to a study.
Advanced liver fibrosis a red flag for poor outcomes in T2D
18 Jul 2023
SGLT2 inhibitors tied to kidney benefits, reduced MACE risk
Treatment with sodium-glucose lowering co-transporter 2 inhibitors (SGLT2i) helps arrest the decline in estimated glomerular filtration rate (eGFR) and is associated with a lower risk of adverse kidney events among adults with diabetes, irrespective of baseline albuminuria status, as shown in a study presented at the recent ADA 2023.
SGLT2 inhibitors tied to kidney benefits, reduced MACE risk
17 Jul 2023
Meal replacement trumps food-based diet for improving CV risk factors in obese adults
In the secondary and exploratory analyses of the OPTIWIN trial, meal replacement (MR) outdid a food-based (FB) regimen in improving cardiometabolic risk in adults with obesity.
Meal replacement trumps food-based diet for improving CV risk factors in obese adults
17 Jul 2023
Danuglipron helps with glucose control, weight loss in T2D
The glucagon-like peptide 1 receptor (GLP-1R) agonist danuglipron appears to be beneficial in the treatment of patients with type 2 diabetes (T2D), yielding reductions in glycated haemoglobin (HbA1c), fasting plasma glucose (FPG), and body weight, without fasting restrictions, as shown in the results of a phase IIb study.